Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report

Curr Oncol. 2022 Jun 15;29(6):4267-4273. doi: 10.3390/curroncol29060341.


Systemic combination therapy of immune checkpoint inhibitors and vascular endothelial growth factors have provided the basis for improved outcomes in select patients with unresectable or metastatic hepatocellular carcinoma. However, for patients with resectable disease, surgery alone or an orthotopic liver transplant remains the standard of care. Within the realms of transplant oncology, neoadjuvant systemic therapy is currently being evaluated as a potential strategy to improve outcomes in patients with HCC. Here, we report excellent response with significant downstaging in a safe manner after neoadjuvant treatment with atezolizumab and bevacizumab in a patient diagnosed with poorly differentiated HCC. As a result of the significant response observed with safe outcomes, the patient was listed for orthotopic liver transplant (OLT) evaluation and transplanted successfully.

Keywords: CTLA-4 inhibitors; PD-1 inhibitors; hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; liver transplantation; transplant oncology.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain / etiology
  • Aged
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / drug therapy
  • Liver Transplantation* / adverse effects
  • Male
  • Neoadjuvant Therapy

Grant support

This research received no external funding.